Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Ocular Therapeutix, Inc. (OCUL) had Cost of Goods Sold of $1.33M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$10.79M |
|
$-88.61M |
|
|
Cost of Goods Sold |
$1.33M |
$9.46M |
|
$104.12M |
|
$-93.34M |
|
$4.73M |
|
$-88.61M |
|
$-88.61M |
|
$-88.61M |
|
$-88.61M |
|
$-88.61M |
|
$-88.61M |
|
$-93.34M |
|
$-92.06M |
|
224.10M |
|
224.10M |
|
$-0.40 |
|
$-0.40 |
|
| Balance Sheet Financials | |
$706.00M |
|
$18.43M |
|
$26.53M |
|
$732.53M |
|
$47.68M |
|
$72.06M |
|
$103.27M |
|
$150.96M |
|
$581.57M |
|
$581.57M |
|
$581.57M |
|
218.90M |
|
| Cash Flow Statement Financials | |
$-65.99M |
|
$-4.66M |
|
$0.29M |
|
$738.67M |
|
$668.31M |
|
$-70.36M |
|
$15.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.81 |
|
-- |
|
-- |
|
0.11 |
|
0.12 |
|
87.68% |
|
-865.46% |
|
-865.46% |
|
-- |
|
-821.62% |
|
-821.62% |
|
$-70.66M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
0.36 |
|
0.44 |
|
203.17 |
|
-15.24% |
|
-15.24% |
|
-12.10% |
|
-13.56% |
|
$2.66 |
|
$-0.32 |
|
$-0.29 |
|